Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: A composition for administration to a subject is disclosed and the composition comprises a vaccine and plinabulin without or with an adjuvant to induce, enhance or boost humoral response. A method of treatment by administering a vaccine and plinabulin is disclosed. A method of enhancing an immune response to a vaccine in a subject by administering to the subject a vaccine and plinabulin is also disclosed. The vaccine and plinabulin can be administered concurrently or separately.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Plinabulin and one or more G-CSF drugs are used for treating a chemotherapy induced neutropenia, stimulating neutrophil survival, reducing bone pain induced by the G-CSF drug and alleviating immune suppression effect induced by the G-CSF drug. For example, docetaxel-induced neutropenia can be reduced by-co-administering plinabulin and one or more G-CSF compounds.

Abstract: Disclosed herein are compositions and methods of preventing and/or treating or reducing immunotherapy mediated adverse events by administering plinabulin. Some embodiments relate to treatment of immunotherapy related inflammation by administering plinabulin. Some embodiments relate to treatment of psoriasis and/or inflammation by administering plinabulin.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: The present invention relates to methods and compositions for treating RA in subjects in need thereof. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.

Abstract: This patent describes a novel in vitro cell-based method for biological validation and pharmacological screening of drugs, new chemical entities (NCEs) and biologics, which is predictive of in vivo testing for efficacy and adverse events in patients, as occurs in clinical trials. The same method can be used to create an in vitro cell-based assay to identify the ‘right marketed medication for the right patient’ (personalized medicine), and to identify responders and non-responders in ongoing clinical trials with NCEs.